Innate and adaptive immune system cells

Innate and adaptive immune system cells, including macrophages, neutrophils, natural killer (NK) cells, and lymphocytes, constitute the primary defense mechanism against infectious agents and tumors. These cellular populations are the functional targets of Azoximer bromide (Polyoxidonium), a synthetic high-molecular-weight polymer used as an immunomodulator and vaccine adjuvant (Dyakov et al., 2015, PubMed). Azoximer bromide enhances the activity of these cells by stimulating phagocytosis, increasing the production of pro-inflammatory cytokines, and promoting the activation of NK cells (Kharit et al., 2017, PubMed). In the context of adaptive immunity, it facilitates the production of specific antibodies by B-lymphocytes, thereby improving the overall immune response to antigens (Pukhalsky et al., 2003, PubMed). The interaction between the drug and these immune cells also provides antioxidant protection and detoxification, which is particularly beneficial during acute inflammatory states (Vavilin et al., 2015, PubMed). Clinically, this target-drug interaction is leveraged to treat chronic recurrent infections and to boost the efficacy of vaccines.

Other names

Immune system cellsLeukocytesWhite blood cellsPhagocytes and lymphocytes

Azoximer bromide (Polyoxidonium) acts as an immunomodulator by directly stimulating the functional activity of innate immune cells (macrophages, neutrophils, and natural killer cells) and enhancing the adaptive immune response through increased antibody production by B-lymphocytes (Dyakov et al., 2015, PubMed).